JP2023504166A5 - - Google Patents

Info

Publication number
JP2023504166A5
JP2023504166A5 JP2022532695A JP2022532695A JP2023504166A5 JP 2023504166 A5 JP2023504166 A5 JP 2023504166A5 JP 2022532695 A JP2022532695 A JP 2022532695A JP 2022532695 A JP2022532695 A JP 2022532695A JP 2023504166 A5 JP2023504166 A5 JP 2023504166A5
Authority
JP
Japan
Prior art keywords
pain
drug
aforementioned
dose
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022532695A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023504166A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/063471 external-priority patent/WO2021113757A1/en
Publication of JP2023504166A publication Critical patent/JP2023504166A/ja
Publication of JP2023504166A5 publication Critical patent/JP2023504166A5/ja
Pending legal-status Critical Current

Links

JP2022532695A 2019-12-06 2020-12-04 疼痛の治療のためのＫｖ７カリウムチャネル開口薬の使用 Pending JP2023504166A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962945093P 2019-12-06 2019-12-06
US62/945,093 2019-12-06
US201962948010P 2019-12-13 2019-12-13
US62/948,010 2019-12-13
PCT/US2020/063471 WO2021113757A1 (en) 2019-12-06 2020-12-04 Use of a kv7 potassium channel opener for treating pain

Publications (2)

Publication Number Publication Date
JP2023504166A JP2023504166A (ja) 2023-02-01
JP2023504166A5 true JP2023504166A5 (enExample) 2023-12-12

Family

ID=73856375

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022532695A Pending JP2023504166A (ja) 2019-12-06 2020-12-04 疼痛の治療のためのＫｖ７カリウムチャネル開口薬の使用

Country Status (14)

Country Link
EP (1) EP4069211A1 (enExample)
JP (1) JP2023504166A (enExample)
KR (1) KR20220113411A (enExample)
CN (1) CN114786658A (enExample)
AU (1) AU2020397173A1 (enExample)
BR (1) BR112022010733A2 (enExample)
CA (1) CA3159436A1 (enExample)
CL (1) CL2022001477A1 (enExample)
CR (1) CR20220318A (enExample)
IL (1) IL293504A (enExample)
MX (1) MX2022006877A (enExample)
PE (1) PE20221169A1 (enExample)
TW (1) TW202133847A (enExample)
WO (1) WO2021113757A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110511220B (zh) 2018-05-22 2022-04-01 上海挚盟医药科技有限公司 作为钾通道调节剂的对二氨基苯衍生物、其制备方法及其在医药上的应用
CN113698345B (zh) * 2021-10-27 2022-02-01 上海挚盟医药科技有限公司 作为钾通道调节剂的化合物及其制备和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
US7553858B2 (en) * 2003-12-17 2009-06-30 Meda Pharma Gmbh & Co. Kg Combination of flupirtine and tramadol
NZ575652A (en) 2006-08-23 2011-08-26 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
WO2013067591A1 (en) * 2011-11-10 2013-05-16 Relevare Australia Pty Ltd Topical formulations for pain management
US9248122B2 (en) * 2012-11-28 2016-02-02 Grünenthal GmbH Heteroquinoline-3-carboxamides as KCNQ2/3 modulators
MA52569B1 (fr) * 2018-05-11 2023-11-30 Xenon Pharmaceuticals Inc Méthodes pour améliorer la biodisponibilité et l'exposition d'un activateur de canal potassique voltage-dépendant

Similar Documents

Publication Publication Date Title
US6248789B1 (en) Administration of ketamine to manage pain and to reduce drug dependency
CN1468111A (zh) 治疗急性、慢性疼痛和/或神经病性疼痛和偏头痛的药物组合物
RU2004137091A (ru) Применение соединений, которые являются эффективными как селективные модуляторы опиатного рецептора
US6538008B1 (en) Combination of a selective NMDA NR2B antagonist and an opioid analgesic
JP2009073842A (ja) 苦痛を管理しおよび薬物依存性を軽減するための、ケタミンの投与
US6979689B2 (en) Compositions and methods for treating upper respiratory congestion
JP2006514056A (ja) ベンズアミド化合物を使用する痛みおよび外傷性傷害の処置方法ならびにベンズアミド化合物を含有する組成物
WO2004064753A3 (en) Use of n-desmethylclozapine to treat human neuropsychiatric disease
CN1413111A (zh) 右美沙芬和氧化酶抑制剂使患者摆脱麻醉药和抗抑郁药的用途
EA002554B1 (ru) Применение кабэрголина при лечении синдрома усталых ног
JP2006510618A (ja) ノルケタミンおよびケタミン／ノルケタミンプロドラッグの鎮痛的使用
WO2013063263A1 (en) Pharmaceutical compositions for treating pain
IL315023A (en) Neuroactive steroids for treatment of cns-related disorders
RU2004119854A (ru) Способы терапии
EP4520394A3 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
US20110008431A1 (en) Therapeutic tablet for postherpetic neuralgia and method of treating postherpetic neuralgia
NO309965B1 (no) Oralt farmasøytisk antihostepreparat
RU2002102076A (ru) Фармацевтическая композиция, содержащая сибутрамин и орлистат
JP2023504166A (ja) 疼痛の治療のためのＫｖ７カリウムチャネル開口薬の使用
US20080132531A1 (en) Synergistic combinations of norketamine and opioid analgesics
US20140148465A1 (en) Compositions and Methods to Improve Treatment of Medical Conditions Using D-Cycloserine
CA2576926A1 (en) Use of midostaurin for treating gastrointestinal stromal tumors
HK1058899A (en) A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
RU2002128958A (ru) Способ лечения онкологических больных
Turner para-Aminobenzoic acid. Nutrient.